All In Biotech

Drug Trial Radar · NCT07237568

A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of LNK01001 in Adult Subjects With Active Ankylosing Spondylitis

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 352 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

352

Planned (sponsor's estimate)

Start

Aug 29, 2025

Primary completion

Nov 2026

Study completion Sep 2027

Sponsor

Lead sponsor
Lynk Pharmaceuticals Co., LtdIndustry
Sponsor type
Industry
First posted
Nov 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy and safety of LNK01001 in subjects with active ankylosing spondylitis. The study is comprised of a 16-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 36-week open-label, long-term extension period (the Open-Label Extension Period). In the Double-Blind Period, participants will be randomized in a 1:1 ratio to receive either LNK01001 or placebo twice daily (BID). Participants in the placebo group will be switched to LNK01001 BID at Week 16 in the Open-Label Extension Period.

Conditions

  • Ankylosing Spondylitis

Interventions

  • LNK01001Drug

    Capsule; Oral

  • PlaceboDrug

    Capsule; Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 16Time frame: Baseline and week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.